NantHealth Inc. (NH)

3.22
NASDAQ : Technology Services
Prev Close 3.28
Day Low/High 3.20 / 3.31
52 Wk Low/High 2.60 / 5.26
Avg Volume 72.50K
Exchange NASDAQ
Shares Outstanding 108.59M
Market Cap 356.18M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NantHealth Unveils Liquid GPS™, Powerful Next-Generation Tool For Blood-Based Tumor Profiling And Quantitative Monitoring

NantHealth Unveils Liquid GPS™, Powerful Next-Generation Tool For Blood-Based Tumor Profiling And Quantitative Monitoring

NantHealth, Inc. (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, unveiled Liquid GPS™ a powerful next-generation tool for blood-based tumor profiling and quantitative monitoring.

NantOmics Announces Study Showing Signature Analysis That Reveals Three Distinct Classifications Of Skin Cancer Known As Sebaceous Carcinoma

NantOmics Announces Study Showing Signature Analysis That Reveals Three Distinct Classifications Of Skin Cancer Known As Sebaceous Carcinoma

NantOmics, LLC, the leader in molecular analyses and a member of the NantWorks ecosystem of companies, announced today the publication of peer-reviewed research defining for the first time three distinct classifications of sebaceous carcinoma, a rare and...

NantHealth To Present At The Bank Of America Merrill Lynch Health Care Conference 2018 On May 17

NantHealth To Present At The Bank Of America Merrill Lynch Health Care Conference 2018 On May 17

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that its management will be presenting at the Bank of America Merrill Lynch 2018 Health Care Conference on Thursday, May 17, 2018, at...

NantHealth Showcases And Presents Its Portfolio Of Medical Device Integration (MDI) Products To Provide Current And Future Insights To Patient Care At The Largest E-Health Event In Scandinavia

NantHealth Showcases And Presents Its Portfolio Of Medical Device Integration (MDI) Products To Provide Current And Future Insights To Patient Care At The Largest E-Health Event In Scandinavia

NantHealth (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, showcased their Connected Care solutions at Vitalis, the largest e-health event in Scandinavia.

CORRECTING And REPLACING NantHealth Reports 2018 First-Quarter Financial Results

CORRECTING And REPLACING NantHealth Reports 2018 First-Quarter Financial Results

Changes have been made to the "Supplemental Revenue Schedule" and "Non-GAAP Net Loss and Non-GAAP Net Loss Per Share" financial tables.

NantHealth And NantOmics Announce Publication Of Study Highlighting High Error Rates In Tumor-Only Sequencing For Cancer Treatment

NantHealth And NantOmics Announce Publication Of Study Highlighting High Error Rates In Tumor-Only Sequencing For Cancer Treatment

NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, and NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, announced today joint results that...

NantHealth To Report 2018 First-Quarter Financial Results And Host Conference Call On Wednesday, May 9

NantHealth To Report 2018 First-Quarter Financial Results And Host Conference Call On Wednesday, May 9

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 first quarter on Wednesday, May 9, 2018, after market close.

NantHealth Reports 2017 Fourth-Quarter And Full-Year Financial Results

NantHealth Reports 2017 Fourth-Quarter And Full-Year Financial Results

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2017.

NantHealth To Report 2017 Fourth-Quarter And Full-Year Financial Results And Host Conference Call On Wednesday, March 14

NantHealth To Report 2017 Fourth-Quarter And Full-Year Financial Results And Host Conference Call On Wednesday, March 14

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2017 fourth quarter and full year on Wednesday, March 14,...

NantHealth To Present On The Future Of Device Connectivity Across The Continuum Of Care At HIMSS18

NantHealth To Present On The Future Of Device Connectivity Across The Continuum Of Care At HIMSS18

NantHealth (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will be exhibiting this year at the Healthcare Information & Management Systems Society Annual Conference & Exhibition...

Short Interest Moves 11.5% Lower For NH

Short Interest Moves 11.5% Lower For NH

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 362,158 share decrease in total short interest for NantHealth Inc , to 2,775,639, a decrease of 11.54% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Tronc Sells Los Angeles Times After Battle With Shareholder

Tronc Sells Los Angeles Times After Battle With Shareholder

Tronc's No. 2 shareholder, billionaire Patrick Soon-Shiong, will pay $500 million and assume $90 million in pension liabilities to acquire the Los Angeles newspaper as well as The San Diego Union-Tribune.

Tronc Will Reportedly Sell Los Angeles Times for $500 Million

Tronc Will Reportedly Sell Los Angeles Times for $500 Million

Move would return Southern California paper to local control for first time in 18 years.

Commit To Buy NantHealth At $2.50, Earn 12.2% Annualized Using Options

Commit To Buy NantHealth At $2.50, Earn 12.2% Annualized Using Options

Investors eyeing a purchase of NantHealth Inc stock, but tentative about paying the going market price of $3.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 20 cents.

NantWorks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA

NantWorks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA

NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.

NantHealth To Support The University Of California San Francisco In Research Initiative Focused On Metastatic Breast Cancer

NantHealth To Support The University Of California San Francisco In Research Initiative Focused On Metastatic Breast Cancer

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced its support for a research study initiated by the University of California, San Francisco (UCSF)...

NantHealth Ranked Number 304 Fastest Growing Company In North America On Deloitte's 2017 Technology Fast 500™

NantHealth Ranked Number 304 Fastest Growing Company In North America On Deloitte's 2017 Technology Fast 500™

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today a ranking of 304 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing...

NantHealth Reports 2017 Third Quarter Financial Results; GPS Revenue Doubles From Preceding Quarter

NantHealth Reports 2017 Third Quarter Financial Results; GPS Revenue Doubles From Preceding Quarter

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its third quarter ended September 30, 2017.

NantHealth To Report 2017 Third-Quarter Financial Results And Host Conference Call On Thursday, November 9

NantHealth To Report 2017 Third-Quarter Financial Results And Host Conference Call On Thursday, November 9

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2017 third quarter on Thursday, November 9, 2017, after...

NantHealth's Vitality Mobile App Now Available On Apple And Android Devices

NantHealth's Vitality Mobile App Now Available On Apple And Android Devices

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that its Vitality Mobile app is now available for download through the Apple and Google Play Stores.

Commit To Buy NantHealth At $2.50, Earn 9.9% Annualized Using Options

Commit To Buy NantHealth At $2.50, Earn 9.9% Annualized Using Options

Investors eyeing a purchase of NantHealth Inc stock, but cautious about paying the going market price of $3.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $2.50 strike, which has a bid at the time of this writing of 10 cents.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Investigation Into NantHealth, Inc. (NASDAQ: NH)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Investigation Into NantHealth, Inc. (NASDAQ: NH)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that it is investigating NantHealth, Inc.

NantHealth And Asia Genomics Announce Global Expansion Of GPS CancerTM in Southeast Asia

NantHealth And Asia Genomics Announce Global Expansion Of GPS CancerTM in Southeast Asia

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced that it has entered into an agreement for  GPS Cancer, the leading proteogenomic molecular test...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DPLO, ERJ, HOLI, OSIS Downgrades: ABG, AMS, BP, BWINB, CYBR, ISSC, LYTS, MXL, NAT, NNA, NSU, TUP Initiations: ESDI, NH Read on to get TheStreet Quant Ratings' detailed report:

NantHealth Reports 2017 Second Quarter Financial Results; Implements Plan To Focus On Core Competencies, Enhance Profitability And Position For Growth Of Artificial Intelligence For Cancer Care

NantHealth Reports 2017 Second Quarter Financial Results; Implements Plan To Focus On Core Competencies, Enhance Profitability And Position For Growth Of Artificial Intelligence For Cancer Care

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its second quarter ended June 30, 2017.

NantHealth To Report 2017 Second-Quarter Financial Results And Host Conference Call On Thursday, August 10

NantHealth To Report 2017 Second-Quarter Financial Results And Host Conference Call On Thursday, August 10

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2017 second quarter on Thursday, August 10, 2017, after...

NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Genomic Profiling To Patients In Mexico

NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Genomic Profiling To Patients In Mexico

NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that GPS Cancer, a molecular test that helps guide cancer treatment strategies...

TheStreet Quant Rating: D- (Sell)